What Does Eyp Mean? the Story Behind Eyepoint's Duravyu Implant and Phase 3 Trial Results

Is what Does Eyp Mean? the Story Behind Eyepoint's Duravyu Implant and Phase 3 Trial Results a topic you are researching? Find out expert analysis in our feature story.

EyePoint is not limiting EYP-1901 to geriatric macular degeneration. In March 2026, clinical sites began dosing patients in global Phase 3 trials evaluating DURAVYU for diabetic macular edema (DME).

DME affects a much younger, working-age demographic. These patients often work full-time jobs, navigate systemic diabetic complications, and miss regular eye clinic appointments at high rates. A working parent who misses work eight times a year for eye injections often ends up undertreated, risking severe diabetic retinopathy and vision loss.

Vorolanib holds a theoretical advantage here: by inhibiting PDGF receptors alongside VEGFR, the compound may stabilize pericytes, the structural cells that wrap around microvessels. Because diabetic eye disease originates from leaky, damaged capillary walls, dual VEGF/PDGF pathway coverage offers a targeted therapeutic approach. If Phase 3 DME trials replicate the vision preservation seen in wet AMD, EYP could become a primary weapon against diabetic eye disease.